Cargando…

Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol

Guidelines currently state that genetic testing is clinically indicated for all individuals diagnosed with ovarian cancer. Individuals with a prior diagnosis of ovarian cancer who have not received genetic testing represent missed opportunities to identify individuals with inherited high-risk cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Kauffman, Tia L., Prado, Yolanda K., Reyes, Ana A., Zepp, Jamilyn M., Sawyer, Jennifer, White, Larissa Lee, Martucci, Jessica, Salas, Suzanne Bianca, Vertrees, Sarah, Rope, Alan F., Weinmann, Sheila, Henrikson, Nora B., Lee, Sandra Soo-Jin, Feigelson, Heather Spencer, Hunter, Jessica Ezzell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625870/
https://www.ncbi.nlm.nih.gov/pubmed/34834546
http://dx.doi.org/10.3390/jpm11111194
_version_ 1784606527336742912
author Kauffman, Tia L.
Prado, Yolanda K.
Reyes, Ana A.
Zepp, Jamilyn M.
Sawyer, Jennifer
White, Larissa Lee
Martucci, Jessica
Salas, Suzanne Bianca
Vertrees, Sarah
Rope, Alan F.
Weinmann, Sheila
Henrikson, Nora B.
Lee, Sandra Soo-Jin
Feigelson, Heather Spencer
Hunter, Jessica Ezzell
author_facet Kauffman, Tia L.
Prado, Yolanda K.
Reyes, Ana A.
Zepp, Jamilyn M.
Sawyer, Jennifer
White, Larissa Lee
Martucci, Jessica
Salas, Suzanne Bianca
Vertrees, Sarah
Rope, Alan F.
Weinmann, Sheila
Henrikson, Nora B.
Lee, Sandra Soo-Jin
Feigelson, Heather Spencer
Hunter, Jessica Ezzell
author_sort Kauffman, Tia L.
collection PubMed
description Guidelines currently state that genetic testing is clinically indicated for all individuals diagnosed with ovarian cancer. Individuals with a prior diagnosis of ovarian cancer who have not received genetic testing represent missed opportunities to identify individuals with inherited high-risk cancer variants. For deceased individuals, post-mortem genetic testing of pathology specimens allows surviving family members to receive important genetic risk information. The Genetic Risk Assessment in Ovarian Cancer (GRACE) study aims to address this significant healthcare gap using a “traceback testing” approach to identify individuals with a prior diagnosis of ovarian cancer and offer genetic risk information to them and their family members. This study will assess the potential ethical and privacy concerns related to an ovarian cancer traceback testing approach in the context of patients who are deceased, followed by implementation and evaluation of the feasibility of an ovarian cancer traceback testing approach using tumor registries and archived pathology tissue. Descriptive and statistical analyses will assess health system and patient characteristics associated with the availability of pathology tissue and compare the ability to contact and uptake of genetic testing between patients who are living and deceased. The results of this study will inform the implementation of future traceback programs.
format Online
Article
Text
id pubmed-8625870
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86258702021-11-27 Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol Kauffman, Tia L. Prado, Yolanda K. Reyes, Ana A. Zepp, Jamilyn M. Sawyer, Jennifer White, Larissa Lee Martucci, Jessica Salas, Suzanne Bianca Vertrees, Sarah Rope, Alan F. Weinmann, Sheila Henrikson, Nora B. Lee, Sandra Soo-Jin Feigelson, Heather Spencer Hunter, Jessica Ezzell J Pers Med Article Guidelines currently state that genetic testing is clinically indicated for all individuals diagnosed with ovarian cancer. Individuals with a prior diagnosis of ovarian cancer who have not received genetic testing represent missed opportunities to identify individuals with inherited high-risk cancer variants. For deceased individuals, post-mortem genetic testing of pathology specimens allows surviving family members to receive important genetic risk information. The Genetic Risk Assessment in Ovarian Cancer (GRACE) study aims to address this significant healthcare gap using a “traceback testing” approach to identify individuals with a prior diagnosis of ovarian cancer and offer genetic risk information to them and their family members. This study will assess the potential ethical and privacy concerns related to an ovarian cancer traceback testing approach in the context of patients who are deceased, followed by implementation and evaluation of the feasibility of an ovarian cancer traceback testing approach using tumor registries and archived pathology tissue. Descriptive and statistical analyses will assess health system and patient characteristics associated with the availability of pathology tissue and compare the ability to contact and uptake of genetic testing between patients who are living and deceased. The results of this study will inform the implementation of future traceback programs. MDPI 2021-11-13 /pmc/articles/PMC8625870/ /pubmed/34834546 http://dx.doi.org/10.3390/jpm11111194 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kauffman, Tia L.
Prado, Yolanda K.
Reyes, Ana A.
Zepp, Jamilyn M.
Sawyer, Jennifer
White, Larissa Lee
Martucci, Jessica
Salas, Suzanne Bianca
Vertrees, Sarah
Rope, Alan F.
Weinmann, Sheila
Henrikson, Nora B.
Lee, Sandra Soo-Jin
Feigelson, Heather Spencer
Hunter, Jessica Ezzell
Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol
title Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol
title_full Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol
title_fullStr Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol
title_full_unstemmed Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol
title_short Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol
title_sort feasibility of a traceback approach for using pathology specimens to facilitate genetic testing in the genetic risk analysis in ovarian cancer (grace) study protocol
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625870/
https://www.ncbi.nlm.nih.gov/pubmed/34834546
http://dx.doi.org/10.3390/jpm11111194
work_keys_str_mv AT kauffmantial feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol
AT pradoyolandak feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol
AT reyesanaa feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol
AT zeppjamilynm feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol
AT sawyerjennifer feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol
AT whitelarissalee feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol
AT martuccijessica feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol
AT salassuzannebianca feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol
AT vertreessarah feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol
AT ropealanf feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol
AT weinmannsheila feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol
AT henriksonnorab feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol
AT leesandrasoojin feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol
AT feigelsonheatherspencer feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol
AT hunterjessicaezzell feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol